An introduction to Sytrinol™

The Powerful, Scientifically Formulated, All Natural Cardiovascular Health Breakthrough.

Course Description

This course provides you an overview of cardiovascular health in the U.S., National Cholesterol Education cholesterol guidelines, options for supporting heart health and a comparison of those options, as well as compelling information about why Sytrinol™ should be the product you are recommending to your customers.

Introduction

Cardio Vascular Disease (CVD), the number 1 killer in the United States for a century, claims annually as many lives as the next seven leading causes of death combined. This adds up to more than 1.4 million deaths in the United States each year according to the most recent statistics from the American Heart Association (AHA).

As CVD holds steady as the top disease in the United States, it is certain that a large percentage of health conscious consumers will look for natural assistance managing CVD or maintaining heart health.  Sytrinol is the leading natural product for supporting healthy cholesterol levels naturally and helping to maintain a healthy heart.

While other “natural” products have failed to consistently deliver on their claims, Sytrinol has repeatedly succeeded in multiple scientific studies. Sytrinol is also the only natural product on the retail shelf that uses the same ingredients at the same effective dose used in multiple scientific studies with no side effects.

Sytrinol is the solution to providing natural support superior to all other nutritional supplements.

Cardio Vascular Disease (CVD) and Cholesterol Guidelines

Almost 64 million Americans, more than one in five, have at least one type of CVD. Coronary Heart Disease (CHD) is the largest single killer of adults in the United States; every 29 seconds an American experiences a coronary event, and every minute an event is fatal.

Over 40 percent of consumer households currently manage or treat cholesterol, 27 percent treat hypertension and 14 percent treat heart disease, according to the Natural Marketing Institute’s (NMI) Health & Wellness Trends Database. Many are also looking to prevent a build-up of plaque in the arteries, atherosclerosis, which is a major contributor to CHD.

Because heart disease claims more lives than any other condition in the United States (as well as other industrialized countries), the National Heart, Lung and Blood Institute (NHLBI) continues to review risk factors for heart disease. Through their efforts, the NHLBI hopes to find more effective means of prevention. Resulting from the NHLBI was the National Cholesterol Education Program (NCEP). NCEP established new guidelines for a healthy lipid profile.

A comparison of earlier and new cholesterol guidelines can be seen in the table below.

Recommendations endorsed by the National Heart, Lung, and Blood Institute, American Heart Association, and American College of Cardiology. The new guidelines are also expected to Triple the number of people prescribed a cholesterol lowering drug from 13 million to more than 36 million (NYT, July 4, 2004).

Most people don’t realize that for every increase of just 1 point in your total cholesterol level, your chances of a heart attack go up 2% and a rise of just 25 points means a 50% increase to your risk of having a heart attack.

Because of the new cholesterol guidelines, more people with borderline lipid profiles may find their physicians recommending that they begin taking a cholesterol-lowering medication in addition to lifestyle modifications.

These medications typically used to lower cholesterol belong to a drug category known as HMG-CoA reductase inhibitors, or “statins,” because they end with the suffix “-statin.” Commonly used drugs in this category include atorvastatin (Lipitor), cerivastatin (Baycol), lovastatin (Mevacor), pravastatin (Pravachol), rosuvastatin (Crestor) and simvastatin (Zocor). Statins are typically prescribed with the goal of lowering LDL-C. They work on inhibiting cholesterol synthesis and increasing the number of LDL receptors in the liver. They also have a modest effect of increasing HDL-C and lowering triglycerides (TG).

The fact of the matter is that statins are the top selling class of drugs in America. The table below clearly illustrates the incredible amount of money spent on cholesterol lowering pharmaceutical drugs. Projected 2005 sales are close to $24 billion. Of course, the 3 billion dollars the drug makers spent marketing and advertising drugs (statin drug advertisements made up over half of that) certainly helped.

While statins have a clear benefit, they can also have adverse side effects, a risk with any effective drug therapy…

“Consumer group urges ban of cholesterol drug. Concern over side effects of Crestor grows” In a letter published Thursday (June 24,04)in the medical journal “The Lancet”, a consumer advocacy group warns that the danger of such life-threatening side effects is unacceptably high with Crestor, a statin that was approved by the Food and Drug Administration last August (Robert Bazell, NBC News, June 24, 2004)

The most common cholesterol lowering medications are Mevacor, Pravachol, Zocor, Lipitor, Crestor, and Lescol.  These “statin” drugs work on the enzyme, HMG CoA-reductase (the rate-limiting enzyme responsible for cholesterol synthesis) by blocking the receptor site that HMG CoA-reductase would normally attach itself to.  This competitive inhibition by statins on the receptor site lowers the total cholesterol, but the enzyme cannot attach to the receptor site and triggers an adaptive response that can yield a 200-fold increase in reductase levels within a few hours. This increase in the HMG CoA-reductase enzyme is the possible reason for the “statin” side effects. Additionally, CoQ10 also shares the same biosynthetic pathway as cholesterol synthesis¹. Consequently, the statins medication causes an unintentional inhibition of CoQ10 synthesis. Statin drugs in the end could predispose the patients to heart disease by lowering their CoQ10 status, the very condition that these drugs are intended to prevent.

1 Bliznakov, EG. Coenzyme Q10, Lipid-Lowering Drugs (Statins) and Cholesterol: A present day pandora’s box. JANA., Vol 5. No. 3, 2002.

Possible statin side effects:

• Rhabdomyolysis (Muscle pain and weakness – when they get into muscle tissue it can begin to break down.)
• Polyneuropathy (Nerve damage – Chances of nerve damage were 26 times higher than the normal population.)
• Brain and central nervous system (after prolonged use some patients suffered measurable decline in cognition)
• Myopathy problems
• Long term use of statins increases the risk of cancer
• Liver problems and elevated liver function tests
• Arthralgias (joint pains)
• Heart failure
• Myositis (muscle inflammation)
• The list goes on . . .

These drugs are expensive with a cost per day, depending on dosage (the dosage range is 10-80 mg per day) of $3-8 per day or $90-240 per month.

Health conscious consumers are seeking natural products that will allow them to maintain their desired quality of life. These natural products either attempt to (1) block the absorption of cholesterol in the gastrointestinal tract, (2) block the production of cholesterol and triglycerides in the liver, or optimally, (3) target both of these mechanisms by combining the best natural alternatives from both categories by utilizing Sytrinol™ and SterolSource™ plant sterols.

Since endogenous synthesis of cholesterol in the liver is responsible for about 80% of our total cholesterol, it makes sense to develop products that work to inhibit HMG-CoA reductase. By inhibiting this mechanism in the liver, statin drugs have been able to show dramatic decreases in total cholesterol, but they also block CoQ10 production. You will commonly hear doctors recommending their patients take CoQ10 supplements along with their statin drugs to help offset the side effects. Sytrinol also works in the liver by inhibiting HMG-CoA reductase, but it does so without inhibiting the production of CoQ10, which is why there have been no reported side effects in our multiple human clinical trials.

The most common natural product that acts to block the absorption of cholesterol in the gastrointestinal tract is plant sterols. The American Heart Association recommends to first try the Step I cholesterol lowering diet and exercise to lower cholesterol, but when diet and exercise aren’t enough, the AHA also recommends adding natural plant sterols twice daily to your diet to help block the absorption of cholesterol in the foods we eat.

The FDA has approved a health claim for these natural cholesterol blockers, but Sytrinol is a new dietary supplement made from natural citrus and palm fruit extracts that should be included in this natural approach based upon research published in the “Journal of Agricultural and Food Chemistry” and multiple clinical trials.

The great thing about plant sterols is they are very affordable, safe, mild to no side effects, and they have a synergistic effect on heart health when combined with Sytrinol.

Recently, SourceOne has launched a proprietary phytosterol called SterolSource™ Phytosterols.  Click here for more information. 

Sytrinol, combined with SterolSource plant sterols, relates to the two sources of cholesterol—the first is food, the second is one’s body. Sytrinol deals with cholesterol produced by the body, based on family history. SterolSource™ plant sterols deal with the cholesterol from the foods we eat. The two sources of cholesterol are at the heart of this patent pending combination branded Cholesstrinol™. For more information on these products, please visit www.source-1-global.com

Sytrinol provides a safe, cost-effective, efficacious and natural source solution. KGK Synergize developed Sytrinol™ and owns the patents, intellectual property and trademark. SourceOne is the exclusive worldwide licensee and marketer of Sytrinol intellectual property and patents for use in nutritional supplements.

Sytrinol is a patented and proprietary formula derived from natural citrus and palm fruit extracts. It combines polymethoxylated flavones (PMFs) delta, gamma, and alpha tocotrienols and other proprietary constituents. Multiple clinical trials have demonstrated that Sytrinol acts synergistically to significantly improve total cholesterol, LDL cholesterol, and triglycerides up to 30%, 27%, and 34%, respectively, compared to placebo.

Sytrinol Clinical Study Results

1. Triglyceride benefits (PMFs): PMFs are known to reduce DGAT activity (diacylglycerol acteyl transferase) and increase liver PPAR (peroxisome proliferator-activated receptor) – and in doing so, reduce overall synthesis of TG (DGAT inhibition) and increase fatty acid oxidation (PPAR activation) – thus reducing TG levels in the blood by two complementary mechanisms.
2. LDL benefits (PMFs): PMFs are known to reduce both Apolipoprotein B levels (ApoB – needed for the synthesis of LDL particles) and MTTP levels (microsomal triglyceride transfer protein – needed to transfer fat into the new LDL particles).
3. Total Cholesterol benefits (Tocotrienols): The proprietary blend of tocotrienols in Sytrinol work by inhibiting the rate-limiting enzyme HMG-CoA reductase4-6. However, Sytrinol’s mode of action contrasts with the competitive inhibition of HMG-CoA reductase receptors exhibited by statins. The hypocholesterolemic effect of Sytrinol appears to act via a novel post-transcriptional process that controls the degradation rate of the HMG-CoA reductase enzyme. In other words, rather than actually preventing the biosynthesis of HMG-CoA reductase enzyme, the tocotrienols present in Sytrinol reduce the levels of this important enzyme required for cholesterol biosynthesis by increasing the rate at which the enzyme molecules degrade. The tocotrienol isoprenoid side-chain causes an increase in the concentration of cellular farnesol. Farnesol is derived from mevalonate, the product of the HMG-CoA reductase reaction. Farnesol, post-transcriptionally, suppresses HMG-CoA reductase activity and enhances the proteolytic catabolism of this enzyme. This mechanism is different from that of the statin hypocholesterolemic drugs which are competitive inhibitors of the enzyme. Sytrinol increases the rate of natural degradation of HMG-CoA reductase and reduces total cholesterol without the side effects associated with statins.
4. Anti-inflammatory benefits (PMFs): Inflammation is an emerging trigger in heart disease. Epidemiological studies are beginning to show that CVD is afflicting younger individuals; One third of those are in good health and their cholesterol is within normal ranges. Both men and women in this group can suffer from sudden heart attacks instantly with no warning signs or risk factors known to cause heart disease. Recent research is establishing that inflammation may be the cause, as inflammation causes C – reactive protein (CRP) to be produced in the body which is a known marker for sudden heart attack. Researchers have shown that the presence of CRP in the body is a more reliable predictor of a pending heart attack than any other traditionally known risk factor for heart disease. “Scientific American,” a leading U.S. science magazine devoted an entire feature article in the May 2002 issue to the causes of heart disease. Specific PMFs, including nobiletin and tangeretin, have been studied for their anti-inflammatory properties, suggesting that the PMFs found in Sytrinol would have a positive effect on CRP.
5. Anti-oxidant benefits (PMFs & Tocotrienols): PMFs and Tocotrienols are among many natural antioxidants that have been researched for decades as potent antioxidants. PMFs can help protect blood vessel linings and prevent the oxidation of LDL cholesterol, which can lead to CVD. Tocotrienols are members of the natural vitamin E family and are some of the most powerful membrane bound antioxidants. They have been linked to reduced rates of oxidative damage as well as reduced incidence of chronic diseases such as heart disease and cancer.

To hear a more detailed explanation of Sytrinol’s mechanisms of action, please click on this link to hear a Health Quest Talk Radio interview with Dr. Shawn Talbott.

There have been some natural products introduced in recent years that were expected to deliver the benefits of helping to balance lipid levels, safely and effectively. Unfortunately, products containing other naturally sourced ingredients have failed to consistently deliver on their claims. This failure is characterized by any of the following: negative research results, FDA ruling and banning of the substance, lack of availability in the U.S. market for the compound used in the clinical trials, and the negative side effects. The evidence is compelling and indisputable and is outlined below. More details are available here.

Product Comparison

Please visit our website at www.source-1-global.com to see the performance comparison chart.

Policosanols – The only clinical trials supporting the efficacy of this ingredient were conducted in Cuba, with Cuban subjects, and with a policosanol material that is not available in the U.S. The positive clinical results, that have been published, have never been repeated or duplicated in the U.S., Canada, Japan or Europe. Several large nutraceutical companies have conducted major studies on policosanols only to be disappointed with the results. The issues of borrowed science and product standardization have raised questions about the efficacy of policosanol materials available outside of Cuba. An industry expert has been quoted in “The Natural Foods Merchandiser” (July 2004) that the policosanol supplements found in the United States are imposters of the real thing. “Policosanol comes from Cuba, and because of the Cuban embargo, true policosanol is not available in the U.S. The supplement that is used here is chemically different than Cuban policosanol and has not been proven to work in any controlled studies.”

Guggulipids – In an article published in August 2003 issue of the “Journal of the American Medical Association,” the lead investigators stated that consuming guggulipids did not have any significant effect on lowering cholesterol levels. The study concluded that guggulipids did not improve levels of serum cholesterol and may in fact raise levels of LDL cholesterol. The “Mayo Clinic Health Letters” (June 2004) and “John Hopkins Med Letter” (February 2004) both reported guggulipids were not effective for lowering cholesterol. More recently, researchers at the University of Kansas found that guggulsterone, the active ingredient in guggulipid, may interfere with nearly 60% of prescription drugs, ironically enough, including anti-cholesterol statin drugs.

Niacin – Niacin has been shown to lower LDL levels at dosages that range up to 4500 mg per day, but results are varied. Additionally, consuming Niacin at high dosages produces numerous side effects including flushing, hot flashes, GI problems and more. The Coronary Drug Project study demonstrated a modest 10% improvement in cholesterol after 6 years of consuming 3000 mg niacin per day (1,119 subjects). Furthermore, the recommended dosage at retail is typically 500 mg per day, but clinical results were achieved at dosages from 100 mg to 4500 mg per day.

Red Yeast Rice – According to the FDA, “red yeast rice products containing standardized lovastatin levels are unapproved new drugs.” The introduction or delivery for introduction of an unapproved new drug into interstate commerce is prohibited under the federal Food, Drug, and Commerce Act (FDCA), sections 301 (d) and 505 (a)”. Red yeast rice supplements currently in the market differ from the standardized extract that demonstrated cholesterol improvement (only positive research was on Cholestin™ marketed by Pharmanex- which is banned). There are no clinical studies on red yeast rice products in retail stores to validate cholesterol management claims at dosages recommended. A study by Dr. Heber (UCLA) found most red yeast rice contains a potentially toxic fermentation product called citrinin. Cholestin™ was produced using a proprietary fermentation process.

Garlic – In a 2001 review on garlic and its effects on cholesterol, Caron and White concluded that a “meta-analysis of 13 garlic clinical trials cause a modest effect on improving cholesterol levels.” Thus, the overall evidence of garlic’s ability to improve cholesterol levels is questionable. Recent studies have shown that the active component of garlic is allicin, however, when clinical studies used allicin alone, there was no effect on improving cholesterol levels. Garlic is associated with numerous side effects including heartburn, flatulence, sweating, dermatitis, body and breath odor and lightheadedness. Dr. C. Leige Broadhurst recently wrote the following: multiple studies have shown supplementation on the order of 800-1000 mg/day can lower cholesterol approximately 10%. While this is encouraging, it summarizes the studies that reported significant effects (about half). The other half reported no significant effects from Garlic supplementation.

Because Sytrinol works in the liver, it addresses one of the major concerns for the consumer; ease of compliance. This is a major area of consideration when recommending a natural product that supports healthy cholesterol levels naturally, because consumers can take a regimented dosage protocol which fits easily into their daily routines. They do not have to worry about adhering to a complicated dosing regimen—and instead can take Sytrinol prior to, immediately following or directly with their meals—whatever works for them. Consequently, your customers are more likely to take the correct dosage and continue using the product over a long period of time. Because they are more likely to use the product properly, they are much more likely to enjoy positive results.

Sytrinol was developed after 12 years of extensive research on the cardiovascular effects of polymethoxylated flavones and tocotrienols. The health benefits of Sytrinol have been demonstrated in vitro, in vivo, and clinical studies. Toxicity studies have shown that Sytrinol is well tolerated, with no toxic effects following consumption of polymethoxylated flavones in amounts of up to 1% of total dietary intake, or the equivalent of a 150-pound individual consuming almost 14 grams per day—that’s nearly 50 times the recommended daily dosage of 300mg/day (NNFA 2004 abstract).

Building brand awareness requires effective alliances and shared commitments between SourceOne™, our brand-manufacturing partners and retailers. Protecting intellectual property with the necessary patents insures that the investment in building the Sytrinol brand and consumer awareness of its health benefits is safe and secured.

SourceOne is committed to a national advertising and PR campaign designed to educate health conscious consumers and create awareness for the Sytrinol™ brand. The most important element of SourceOne’s overall marketing and communication plan is to integrate Sytrinol’s brand marketing strategy and the individual co-promotion programs by our manufacturing partners into one comprehensive and compelling campaign. By doing so, we will effectively communicate Sytrinol’s unparalleled value to consumers seeking cardiovascular wellness and a natural solution to the cholesterol problem.

SourceOne continues to invest in building the Sytrinol brand. The supporting science is critical for success and we recently completed another clinical trial with a fifth starting in August 2005. What is even more profound about this fact is that we are developing the newest supporting science for plant sterols in a delivery system other than a food product. The patent-pending combination of patented Sytrinol and SterolSource plant sterols sets us apart from even the large vertically integrated soy processors that produce plant sterols.

We continue to invest in our national advertising campaign. You’ve seen our ads strategically placed in leading publications such as Natural Foods Merchandiser, Functional Foods & Nutraceuticals and Delicious Living. We coordinate other key elements of our marketing campaign like spokesperson support, compelling editorials, press releases, important trade shows, radio interviews and lectures so they are integrated for maximum effect. A detailed schedule of SourceOne’s marketing and advertising initiatives is available upon request. We strategically plan to take advantage of important awareness building opportunities like National Cholesterol Education Month, which is September 2005. What do we have planned?

• New Sytrinol video news release (VNR) This 90 second video news release will be distributed to over 1100 television news stations, with over a million viewers.
• Nutrilearn Training Course launch. This teaching tool allows sales people, and all interested parties, to learn the ins and outs of Sytrinol including scientific data, proper dosage and product comparisons. A certificate of recognition is awarded after taking the course and successfully passing the test.
• PR campaign promoting the supporting science for Sytrinol.
• New direct mail campaign
• Revised and updated Sytrinol brochure
• Sytrinol featured on multiple health topic radio programs such as Health Quest Radio. Visit www.healthquestradio.com to hear a very compelling and informative interview.
• Online advertising and sponsorships of important websites and newsletter such as NutraIngredients.com, NutraIngredientsUSA.com, and HSC newsletter.
• New shelf talkers and consumer brochures for retailers
• Re-prints of editorials featuring Sytrinol in magazines like Total Health.
• Updated SourceOne web site and Sytrinol information
• Sales training and training materials
• Supplement Watch Feature on Sytrinol. Please visit www.supplementwatch.com to enjoy the feature.

The above initiatives combined with customized co-promotion programs with leading brands represent a thorough and complete advertising and communications plan that include all the necessary ingredients for success.

We must continue to invest and build on the momentum we will have launching into the New Year. SourceOne has made plans for even greater Sytrinol brand building success in 2006.

SourceOne is currently in the final stages of establishing its scientific board.   Dr. Michael Davidson, a leading cardiologist and chair of the Lipid clinic at Rush University Medical Center in Chicago, has agreed to be the chairman. He will work with a select group of medical doctors, primarily cardiologists, to provide leadership in the area of non pharmaceuticals that support heart health naturally. Early in the New Year we will launch our new consumer ad campaign, direct response TV, and more.

To further build awareness and create more exposure for Sytrinol, SourceOne will launch a new marketing initiative in February 2006, during Heart Health Month by featuring Sytrinol in the Chris Everett Healthy Living TV program. Details about the program are as follows:

• This Half-hour, magazine-style, entertaining and educational series explores the full range of health and lifestyle issues, as well as human interest stories. Hosted by Chris Everett, the show gives an extraordinary look at the latest innovations in medical and health related products and services. The show airs via national syndication to over 75% of US television households, typically during late mornings and afternoon time periods on weekends, primarily on affiliates of ABC, CBS, NBC and FOX. Each show is TV Guide Listed. Additionally, the show is broadcasted by satellite on the Dish Network, on Turner Media Groups “Healthy Living Channel”. Delivered to 12.3 million households. On “Healthy Living Channel” it will air 3 times, two of which are in Prime Time. Sytrinol’s segment will be individually promoted across 9 Turner Media Group channels on the Dish Network, including The Men’s Channel, The Beauty & Fashion Channel and iShop TV. In this airing you may include your phone number and web site at the end of the segment.
• Additionally, a 60 second Radio News Story will be produced from your segment and broadcast as part of a 30 Minute syndicated radio program "Radio Health Journal" (RHJ). RHJ is broadcast on over 400 stations nation-wide; primarily FM. Station verification will be supplied by every radio station.

Our marketing plans do not stop there. We have secured a full page, four-color ad in the annual issue of Changes, the North American Menopause Society (NAMS) magazine. Sytrinol will be the only heart health product in the magazine. 

One million copies will be printed and 800,000 copies will be distributed directly to physicians (NAMS’ members) and another 200,000 copies will be available at the doctor's waiting rooms. 

There is more, much more! We are planning for success, but will only reach our goal if you join us by building your co-promotion program into what we consider to be one comprehensive and compelling campaign. Thanks in advance for your great ideas and exceptional execution of the plan.

Some products claim to be clinically proven to support healthy cholesterol and triglyceride levels. However, the ingredients used in the clinical trials are either not available to the consumer, or too often, the effective dose used in these trials is not the same dosage found in supplements from retailers. Sytrinol is now available in leading brands- the same ingredients at the same effective dose used in multiple clinical trials. To learn more about Sytrinol and SterolSource from SourceOne, please visit www.source-1-global.com or call us at 1-800-755-4996.

1. KGK Synergize developed Sytrinol and owns the U.S. patents #6,239,114, #6,261,400, patents-pending and international patents.

2. Compositions and methods of treatment of neoplastic diseases and hypercholesterolemia with citrus limonoids and flavonoids and tocotrienols (United States Patent 6,251,400).

3. Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols (United States Patent 6.239,114).

4. Compositions and methods of treatment and prevention of hypercholesterolemia and atherosclerosis with combinations of phytosterols, flavonoids, and tocotrienols (Patent Application No. 60/560,284 – Sytrinol/Sterol combination).

5. Compositions and methods of treating, reducing and preventing cardiovascular diseases and disorders with polymethoxylated flavones (Patent Application No. 09/528,488)

6. Compositions and methods of treatment of neoplastic disease and hypercholesterolemia with citrus flavonoids, limonoids and tocotrienols (Japan Patent application No. PCT/lB98/01721).

7. Compositions and methods for regulating lipoproteins and hypercholesterolemia with limonoids, flavonoids and tocotrienols (PCT Patent Application No. PCT/lB01/00256).

8. Compositions and methods for regulating lipoproteins and hypercholesterolemia with limonoids, flavonoids and tocotrienols (US Patent Application No. 09/481724 ).

9. Compositions and methods of treatment of neoplastic disease and hypercholesterolemia with citrus flavonoids, limonoids, and tocotrienols (Can. Patent Application No. 304202).

10. Compositions and methods of treatment of neoplastic disease and Hypercholesterolemia with citrus flavonoids, limonoids and tocotrienols (EPC Patent Application No. 98947740.1)

11. Composition and method of treating, reducing, and preventing cardiovascular diseases and disorders with polymethoxylated flavones (EPC Application No. 1920415.5).

12. Composition and method of treating, reducing, and preventing cardiovascular diseases and disorders with polymethoxylated flavones (PCT Application No. PCT/US01/08395).

13. KGK Synergize owns US Patent Pending 60/560,284—Sytrinol/Plant Sterol combination and SourceOne has licensed the worldwide marketing rights for this combination in nutritional supplement applications.

Ameer B, Weintraub RA, Johnson JV, Yost RA, Rouseff RL. Flavanone absorption after naringin, hesperidin, and citrus administration. Clin Pharmacol Ther. 1996 Jul;60(1):34-40.

Bok SH, Lee SH, Park YB, Bae KH, Son KH, Jeong TS, Choi MS Plasma and hepatic cholesterol and hepatic activities of 3-hydroxy-3-methyl-glutaryl-CoA reductase and acyl CoA: cholesterol transferase are lower in rats fed citrus peel extract or a mixture of citrus bioflavonoids. J Nutr. 1999 Jun;129(6):1182-5.

Borradaile NM, de Dreu LE, Barrett PH, Behrsin CD, Huff MW. Hepatocyte apoB-containing lipoprotein secretion is decreased by the grapefruit flavonoid, naringenin, via inhibition of MTP-mediated microsomal triglyceride accumulation. Biochemistry. 2003 Feb 11;42(5):1283-91.

Borradaile NM, de Dreu LE, Barrett PH, Huff MW. Inhibition of hepatocyte apoB secretion by naringenin: enhanced rapid intracellular degradation independent of reduced microsomal cholesteryl esters. J Lipid Res. 2002 Sep;43(9):1544-54.

Borradaile, N.M., Carroll, K.K., and Kurowska, E.M., Regulation of HepG2 cell apolipoprotein B metabolism by the citrus flavones hesperitin and naringenin, Lipids, 34: 491-598, 1999

Borradaile, N.M., Carroll, K.K. and Kurowska, E.M. Regulation of apo B metabolism in HepG2 cells by the citrus flavanones hesperetin and naringenin. Lipids 34 (1999) 591-598.

Bors, W., Heller, W., Michel, C., and Saran, M., Flavonoids as antioxidants: determination of radical scavenging efficiencies, Method Enzymol., 186:343-355, 1990.

Cheeke, P.R., Nutrition and nutritional disease, in The Biology of the Laboratory Rabbit, Manning, P.J., Ringler, D.H., and Newcomer, C.E., Eds., Academic Press, San Diego, CA, 1994.

Chiba H, Uehara M, Wu J, Wang X, Masuyama R, Suzuki K, Kanazawa K, Ishimi Y. Hesperidin, a citrus flavonoid, inhibits bone loss and decreases serum and hepatic lipids in ovariectomized mice. J Nutr. 2003 Jun;133(6):1892-7.

Choi, J.S., Yokozawa, T., and Oura, H., Antihyperlipidemic effect of flavonoids from Prunus davidiana, J. Nat. Prod., 54:218-224, 1991.

Cook, N.C. and Samman, S., Flavonoids—chemistry, metabolism, cardioprotective effects, and dietary sources, J. Nutr. Biochem., 7:66-76, 1996.

Dixon JL, Ginsberg HN Regulation of hepatic secretion of apolipoprotein B-containing lipoproteins: information obtained from cultured liver cells. J Lipid Res. 1993 Feb;34(2):167-79. Review

Erlund I, Silaste ML, Alfthan G, Rantala M, Kesaniemi YA, Aro A. Plasma concentrations of the flavonoids hesperetin, naringenin and quercetin in human subjects following their habitual diets, and diets high or low in fruit and vegetables. Eur J Clin Nutr. 2002 Sep;56(9):891-8.

Hansen, M.B., Nielsen, S.E., and Berg, K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Meth., 119:203-210, 1989.

Hayes, K.C., Pronczuk, A. and Liang, J.S. Differences in the plasma transport and tissue concentrations of tocopherols and tocotrienols: Observations in humans and hamsters. P. Soc. Exp. Biol. Med. 202 (1993) 353-359.

Hayes, K.C., Pronczuk, A., and Liang. J.S., Differences in the plasma transport and tissue concentrations of tocopherols and tocotrienols: observatrions in humans and hamsters. P. Soc. Exp. Biol. Med., 202:353-358, 1993.

Horowitz, R.M, Gentili, B. Flavonoid constituents of Citrus. In Citrus Science and Technology; Nagy, S., Shaw, P.E., Veldhuis, M.K., Eds.; Avi Publishing Company, Inc.; Westport, CT, 1977; Vol 1, pp 397-426

Kamat JP, Sarma HD, Devasagayam TP, Naseratnam K and Basiron Y. Tocotrienols from palm oil as effective inhibitors of protein oxidation and lipid peroxidation in rat liver microsomes. Mol. Cell Biochem. 170:131-137, 1997.

Kawaguchi, K., Mizuno, T., Aida, K., and Uchino, K. Hesperidin as an inhibitor of lipases from porcine pancreas and pseudomonas. Biosci. Biotech. Biochem., 61:102-104, 1997.

Khor, H.T., Chieng D.Y., and Ong, K.K. Tocotrienols inhibit liver HMG-CoA reductase activity in the guinea pig. Nutr. Res., 15:537:544, 1995.

Kurowska EM Determination of cholesterol-lowering potential of minor dietary components by measuring apolipoprotein B responses in HepG2 cells. Methods Enzymol. 2001;335:398-404.

Kurowska EM, Manthey JA, Casaschi A, Theriault AG. Modulation of HepG2 cell net apolipoprotein B secretion by the citrus polymethoxyflavone, tangeretin. Lipids. 2004 Feb;39(2):143-51.

Kurowska, E.M. and Borradaile, N.M., Hypercholesterolemic effects of dietary citrus juices in rabbits, Nutr. Res., 20: 121-129, 2000.

Kurowska, E.M., Hrabek-Smith, J.M., and Carroll, K.K., Compositional changes in serum lipoproteins during developing hypercholesterolemia induced in rabbits by cholesterol-free semipurified diets, Atherosclerosis, 78: 159-165, 1989.

Kurowska EM, Manthey JA. Regulation of lipoprotein metabolism in HepG2 cells by citrus flavonoids. Adv Exp Med Biol. 2002;505:173-9. Review.

Kurowska EM, Manthey JA. Hypolipidemic effects and absorption of citrus polymethoxylated flavones in hamsters with diet-induced hypercholesterolemia. J Agric Food Chem. 2004 May 19;52(10):2879-86.

Kurowska, E.M., Morley, K. and Gapor, A. Role of tocotrienols from palm oil in regulation of apo B metabolism in HepG2 cells. Experimental Biology 99, Washington, DC, April 17-21, 1999.

Kurowska, E.M., Morley, K., and Gapor, A. Regulation of apo B production in HepG2 cells by tocotrienols from palm oil. Proceedings, PORIM International Palm Oil Congress, Kuala Lumpur, Malaysia, 212-219, 1999.

Kurowska EM, Spence JD, Jordan J, Wetmore S, Freeman DJ, Piche LA, Serratore P. HDL-cholesterol-raising effect of orange juice in subjects with hypercholesterolemia. Am J Clin Nutr. 2000 Nov;72(5):1095-100.

Manach C, Morand C, Gil-Izquierdo A, Bouteloup-Demange C, Remesy C. Bioavailability in humans of the flavanones hesperidin and narirutin after the ingestion of two doses of orange juice. Eur J Clin Nutr. 2003 Feb;57(2):235-42.

Manthey JA, Grohmann K, Guthrie N. Biological properties of citrus flavonoids pertaining to cancer and inflammation. Curr Med Chem. 2001 Feb;8(2):135-53. Review.

Mensink, R.P., van Houwelingen, A.C., Kromhout, D., and Hornstra, G. A vitamin E concentrate rich in tocotrienols had no effect on serum lipids, lipoproteins, or platelet function in men with mildly elevated serum lipid concentrations. Am. J. Clin. Nutr., 69:213-219, 1999.

Monforte, M.T., Trovato, A., Kirjavainen, S., Forestieri, A.M., and Galati, E.M. Biological effects of hesperidin, a citrus flavonoid. (note II): hypolipidemic activity on experimental hypercholesterolemia in rat. Farmaco 50:595-599, 1995.

Murakami A, Koshimizu K, Ohigashi H, Kuwahara S, Kuki W, Takahashi Y, Hosotani K, Kawahara S, Matsuoka Y. Characteristic rat tissue accumulation of nobiletin, a chemopreventive polymethoxyflavonoid, in comparison with luteolin. Biofactors. 2002;16(3-4):73-82.

Murakami A, Kuwahara, S., Takahashi Y , Ito, C., Furukawa, H., Ju-Ichi, M. In Vitro absorption and metabolism of nobiletin, a chemopreventive polymethoxyflavonoid in citrus fruits. Biosci., Biotechnol., Biochem. 2001. 65. 194-197.

Nielsen SE, Breinholt V, Cornett C, Dragsted LO Biotransformation of the citrus flavone tangeretin in rats. Identification of metabolites with intact flavane nucleus. Food Chem Toxicol. 2000 Sep;38(9):739-46.

Nielsen SE, Breinholt V, Justesen U, Cornett C, Dragsted LO. In vitro biotransformation of flavonoids by rat liver microsomes. Xenobiotica. 1998 Apr;28(4):389-401.

Parker, R.A., Pearce, B.C., Clark, R.W., Gordon, D.A., and Wright J.J.K. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J. Biol. Chem., 268:11230-11238, 1993.

Pearce, B.C., Parker, R.A., Deason, M.E., Quereshi, A.A., and Wright J.J.K. Hypercholesterolemic activity of synthetic and natural tocotrienols. J. Med. Chem., 35:3595-3606, 1992.

Quereshi, A.A., Bradlow, B.A., Brace, L. et al. Response of hypercholesterolemic subjects to administration of tocotrienols. Lipids 30 (1995) 1171-1177.

Quereshi, A.A., Bradlow, B.A., Salser, W.A., and Brace, L.D. Novel tocotrienols of rice bran modulate cardiovascular disease risk parameters of hypercholesterolemic humans. J. Nutr. Biochem., 8:290-298, 1997.

Quereshi, A.A., Pearce, B.C., Nor, R.M., Gapor, A., Peterson, D.M. and Elson. C.E. Dietary a-tocopherol attenuates the impact of g-tocotrienol on hepatic 3-hydroxy-3-methylglutaryl coenzyme a reductase activity in chickens. J. Nutr., 126:389-394, 1996.

Quereshi, A.A., Quereshi, N., Hasler-Rapacz, J.O. et al. Dietary tocotrienols reduce concentrations of plasma cholesterol, apolipoprotein B, tromboxane B2, and platelet factor 4 in pigs with inherited hyperlipidemias. Am. J. Clin. Nutr. 53 (1991) 1042S-1046S.

Quereshi, A.A., Quereshi, N., Wright J.J.K., Shen, Z., Kramer, G., Gapor, A., Chong, Y.H., DeWitt, G., Ong, A.S.H., Peterson, D.M., and Bradlow, B.A. Lowering of serum cholesterol in hypercholesterolemic humans by tocotrienols (palmvitee). Am. J. Clin. Nutr., 53:1021S-1026S, 1991.

Quereshi, N. and Quereshi, A.A. Tocotrienols: Novel hypocholesterolemic agents with antioxidant properties. In: Vitamin E in Health and Disease, Packer L. and Fuchs, J. (eds.) Marcel Dekker, Inc., New York 1993, 247-267.

Shin, Y.W., Bok, S.H., Jeong, T.S., Bae, K.H., Jeoung, N.H., Choi, M.S., Lee, S.H. and Park, Y.B. Hypocholesterolemic effect of naringin associated with hepatic cholesterol regulating enzyme changes in rats. Int. J. Vitam. Nutr. Res. 69 (1999) 341-347.

Spencer JP, Chowrimootoo G, Choudhury R, Debnam ES, Srai SK, Rice-Evans C. The small intestine can both absorb and glucuronidate luminal flavonoids. FEBS Lett. 1999 Sep 17;458(2):224-30

Theriault, A., Chao, J.T., Wang, Q., Gapor, A. and Adeli, K. Tocotrienol: A review of its therapeutic potential. Clin. Biochem 32 (1999) 309-319.

Theriault, A., Wang, Q., Gapor, A., and Adeli, K. Effects of g-tocotrienol on apoB synthesis, degradation, and secretion in HepG2 cells. Arterioscler. Tromb. Vac. Biol., 19:714-712, 1999.

Theriault, A., Wang, Q., Gapor, A., and Adeli, K. Effects of g-tocotrienol on apoB synthesis, degradation, and secretion in HepG2 cells. Arterioscler. Tromb. Vac. Biol., 19:714-712, 1999.

Thrift, R.N., Forte, T.M., Cahoon, B.E., and Shore, V.G., Characterization of lipoprotein produced by the human liver cell line HepG2, under defined conditions, J. Lipid Res., 27: 236-250, 1986.

Tomeo AC, Geller M, Watkins TR, Gapor A and Bierenbaum ML. Antioxidant effects of tocotrienols in patients with hyperlipidemia and carotid stenosis. Lipids 30:1179-1183, 1995.

Watkins, T., Lenz, P., Gapor, A., Struck, M., Tomeo, A., and Bierenbaum, M. g-Tocotrienol as a hypocholesterolemic and antioxidant agent in rats fed atherogenic diet. Lipids 28:1113-1118, 1993.

Wilcox, L.J., Borradaile, N.M. and Huff, M.W. Antiatherogenic properties of naringenin, a citrus flavonoid. Cardiovasc. Drug Rev. 17 (1999) 160-178.

Wilcox LJ, Borradaile NM, de Dreu LE, Huff MW. Secretion of hepatocyte apoB is inhibited by the flavonoids, naringenin and hesperetin, via reduced activity and expression of ACAT2 and MTP. J Lipid Res. 2001 May;42(5):725-34.

Wilcox, L.J., Borradaile, N.M., Kurowska, E.M. Telford, D.E., and Huff, M.W., Naringenin, a citrus flavonoids, markedly decreases apoB secretion in HepG2 cells and inhibits acyl CoA:cholesterol acyltransferase, Circulation, 98: 1-537, 1998.

Delaney B, Phillips K, Vasquez C, Wilson A, Cox D, Wang HB, Manthey J.Genetic toxicity of a standardized mixture of citrus polymethoxylated flavones. Food Chem Toxicol. 2002 May;40(5):617-24.

Delaney B, Phillips K, Buswell D, Mowry B, Nickels D, Cox D, Wang HB, Manthey J. Immunotoxicity of a standardized citrus polymethoxylated flavone extract. Food Chem Toxicol. 2001 Nov;39(11):1087-94.

Kawaii S, Tomono Y, Katase E, Ogawa K, Yano M. Antiproliferative activity of flavonoids on several cancer cell lines. Biosci Biotechnol Biochem. 1999 May;63(5):896-9.

Manthey JA, Guthrie N. Antiproliferative activities of citrus flavonoids against six human cancer cell lines. J Agric Food Chem. 2002 Oct 9;50(21):5837-43.

Manthey JA, Grohmann K. Phenols in citrus peel byproducts. Concentrations of hydroxycinnamates and polymethoxylated flavones in citrus peel molasses. J Agric Food Chem. 2001 Jul;49(7):3268-73.

Manthey JA, Grohmann K, Montanari A, Ash K, Manthey CL. Polymethoxylated flavones derived from citrus suppress tumor necrosis factor-alpha expression by human monocytes. J Nat Prod. 1999 Mar;62(3):441-4.

Mora A, Paya M, Rios JL, Alcaraz MJ. Structure-activity relationships of polymethoxyflavones and other flavonoids as inhibitors of non-enzymic lipid peroxidation. Biochem Pharmacol. 1990 Aug 15;40(4):793-7.

Takanaga H, Ohnishi A, Yamada S, Matsuo H, Morimoto S, Shoyama Y, Ohtani H, Sawada Y. Polymethoxylated flavones in orange juice are inhibitors of P-glycoprotein but not cytochrome P450 3A4. J Pharmacol Exp Ther. 2000 Apr;293(1):230-6.

             
Sytrinol™. It works. It’s natural. It’s proven.